Soleno Therapeutics Enters Material Agreement, Creates Financial Obligation
Ticker: SLNO · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $100.0 million, $25.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
SOLENO just signed a big deal and owes money, filing shows.
AI Summary
On November 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction. This event also created a direct financial obligation for the company. The filing indicates other events and includes financial statements and exhibits.
Why It Matters
This filing signals a significant development for Soleno Therapeutics, potentially impacting its financial standing and future operations due to the new definitive agreement and financial obligation.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to the terms of the agreement and the company's ability to meet its obligations.
Key Players & Entities
- SOLENO THERAPEUTICS, INC. (company) — Registrant
- November 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36593 (commission_file_number) — SEC File Number
- 77-0523891 (ein) — IRS Employer Identification Number
- 100 Marine Parkway, Suite 400 (address) — Principal executive offices
- Redwood City, CA 94065 (address) — Principal executive offices
- 650-213-8444 (phone_number) — Business phone
FAQ
What is the nature of the material definitive agreement entered into by Soleno Therapeutics, Inc. on November 10, 2025?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What type of direct financial obligation was created for Soleno Therapeutics, Inc.?
The filing states that a direct financial obligation was created, but the specific details of this obligation are not provided in the excerpt.
What are the principal executive offices of Soleno Therapeutics, Inc.?
The principal executive offices of Soleno Therapeutics, Inc. are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
When was Soleno Therapeutics, Inc. incorporated?
Soleno Therapeutics, Inc. was incorporated in Delaware.
What is the SEC file number for Soleno Therapeutics, Inc.?
The SEC file number for Soleno Therapeutics, Inc. is 001-36593.
Filing Stats: 1,174 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2025-11-12 06:09:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $100.0 million — ompany shall repurchase an aggregate of $100.0 million of the Company's common stock, $0.001 p
- $25.0 million — vailability of the previously committed $25.0 million Term C Loans and $25.0 million Term D L
Filing Documents
- d63564d8k.htm (8-K) — 33KB
- d63564dex101.htm (EX-10.1) — 190KB
- d63564dex102.htm (EX-10.2) — 56KB
- d63564dex991.htm (EX-99.1) — 6KB
- g63564g1111094710483.jpg (GRAPHIC) — 4KB
- g63564g28e79.jpg (GRAPHIC) — 4KB
- 0001193125-25-275674.txt ( ) — 467KB
- slno-20251110.xsd (EX-101.SCH) — 3KB
- slno-20251110_lab.xml (EX-101.LAB) — 18KB
- slno-20251110_pre.xml (EX-101.PRE) — 11KB
- d63564d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of ASR Agreement 10.2 First Amendment to Loan and Security Agreement, dated as of November 10, 2025, by and among the Company, Essentialis, Inc., Oxford Finance LLC, as collateral agent, and the Lenders party thereto. 99.1 Press Release, dated November 11, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SOLENO THERAPEUTICS, INC. November 12, 2025 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer 5